PAVmed PAVMW 深 沪
交易中 08-28 11:44:25 美东时间
0.029
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.029
- 总市值 38.69万
- 52周最高 4.743
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.02
- 委 比 0.00%
- 总股本 1334.31万
- 历史最高 6.94
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.02
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股前瞻 | 聚焦今夜22点！沃什杰克逊霍尔首秀或“释放重磅信号”；Anthropic最快九月下旬美股上市；迈威尔科技绩后暴跌8%
聚焦今夜22点！沃什杰克逊霍尔首秀或“释放重磅信号”；Anthropic拟募资1300亿美元！最快九月下旬美股上市；迈威尔科技绩后重挫8%，财报强劲市场仍“不买账”>>
今天 20:31
Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Evercore ISI Group raised the price target for Salesforce Inc (NYSE:CRM) from $250 to $290. Evercore ISI Group...
08-27 21:19
Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $57
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $56 to $57.
08-27 19:40
PAVmed GAAP EPS of $0.87
PAVmed press release (PAVM): Q2 GAAP EPS of $0.87. Revenue rose to $33K. PAVmed had cash and cash equivalents of $3.8 million as of June 30, 2026, compared to $1.5 million as of December 31, 2025. Mor...
08-14 20:02
PAVmed Q2 Adj. EPS $(0.27) Beats $(0.58) Estimate, Sales $33.000K Miss $72.000K Estimate
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.58) by 53.45 percent. This is a 82 percent increase over losses of $(1.50) per share from the same period last year. The company reported quarterly sales of $33.000 thousand which mis...
08-14 20:01
Lucid Diagnostics (LUCD) 2026财年第二季度业绩电话会议：营收增长17%，Concert保险覆盖取得进展
Lucid Diagnostics 2026财年第二季度业绩电话会议涵盖了150万美元营收、2,770次 EsoGuard 检测、Concert 保险覆盖范围、Medicare 延迟以及3340万美元现金储备。
08-14 08:28
PAVmed Q2 2026 Earnings Preview
PAVmed (PAVM) is scheduled to announce Q2 earnings results on Friday, August 14th, before market open. The consensus EPS Estimate is -$0.63 and the consensus Revenue Estimate is $0.05M Over the last 2...
08-14 02:46
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of ...
08-04 20:30
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $56
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $65 to $56.
06-08 18:08
PAVmed Earnings Call: Restructuring Done, Execution Ahead
Pavmed (($PAVM)) has held its Q1 earnings call. Read on for the main highlights...
05-16 08:13
